Shenzhen Hepalink Pharmaceutical Files Board of Directors List to HKEX

Reuters12-16

<a href="https://laohu8.com/S/SHEZF">Shenzhen Hepalink</a> Pharmaceutical Files Board of Directors List to HKEX

Shenzhen Hepalink Pharmaceutical Group Co. Ltd. has filed an updated list of directors with the Hong Kong Stock Exchange. The board is led by Executive Director and Chairman Mr. Li Li, who also serves as Chairperson of the Strategy Committee and as a member of the Nomination Committee. Ms. Li Tan, Deputy General Manager, is a member of both the Strategy and Nomination Committees. Mr. Shan Yu, General Manager, and Mr. Zhang Ping also serve as Executive Directors. The company's Independent Non-executive Directors are Mr. Huang Peng, Chairperson of the Audit Committee and member of the Remuneration and Evaluation Committee; Mr. Yi Ming, Chairperson of the Remuneration and Evaluation Committee and member of the Audit and Nomination Committees; and Mr. Pu Hong, Chairperson of the Nomination Committee and member of the Strategy and Audit Committees.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shenzhen Hepalink Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251216-11957365), on December 16, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591731983?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-16 18:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591731983","market":"nz","top_or_hot":-1,"title":"Shenzhen Hepalink Pharmaceutical Files Board of Directors List to HKEX","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SHEZF\">Shenzhen Hepalink</a> Pharmaceutical Files Board of Directors List to HKEX\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/002399\">Shenzhen Hepalink</a> Pharmaceutical Group Co. Ltd. has filed an updated list of directors with the Hong Kong Stock Exchange. The board is led by Executive Director and Chairman Mr. Li Li, who also serves as Chairperson of the <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> Committee and as a member of the Nomination Committee. Ms. Li Tan, Deputy General Manager, is a member of both the <a href=\"https://laohu8.com/S/STRF\">Strategy</a> and Nomination Committees. Mr. Shan Yu, General Manager, and Mr. Zhang Ping also serve as Executive Directors. The company's Independent Non-executive Directors are Mr. Huang Peng, Chairperson of the Audit Committee and member of the Remuneration and Evaluation Committee; Mr. Yi Ming, Chairperson of the Remuneration and Evaluation Committee and member of the Audit and Nomination Committees; and Mr. Pu Hong, Chairperson of the Nomination Committee and member of the Strategy and Audit Committees.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shenzhen Hepalink Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251216-11957365), on December 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shenzhen Hepalink Pharmaceutical Files Board of Directors List to HKEX</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShenzhen Hepalink Pharmaceutical Files Board of Directors List to HKEX\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-16 18:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SHEZF\">Shenzhen Hepalink</a> Pharmaceutical Files Board of Directors List to HKEX\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/002399\">Shenzhen Hepalink</a> Pharmaceutical Group Co. Ltd. has filed an updated list of directors with the Hong Kong Stock Exchange. The board is led by Executive Director and Chairman Mr. Li Li, who also serves as Chairperson of the <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> Committee and as a member of the Nomination Committee. Ms. Li Tan, Deputy General Manager, is a member of both the <a href=\"https://laohu8.com/S/STRF\">Strategy</a> and Nomination Committees. Mr. Shan Yu, General Manager, and Mr. Zhang Ping also serve as Executive Directors. The company's Independent Non-executive Directors are Mr. Huang Peng, Chairperson of the Audit Committee and member of the Remuneration and Evaluation Committee; Mr. Yi Ming, Chairperson of the Remuneration and Evaluation Committee and member of the Audit and Nomination Committees; and Mr. Pu Hong, Chairperson of the Nomination Committee and member of the Strategy and Audit Committees.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shenzhen Hepalink Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251216-11957365), on December 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0070","symbol_name":"员工持股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDLbQZ3vH:1","article_id":"2591731983","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591731983","pubTimestamp":1765881457,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Shenzhen Hepalink Pharmaceutical Group Co. Ltd. has filed an updated list of directors with the Hong Kong Stock Exchange. The board is led by Executive Director and Chairman Mr. Li Li, who also serves as Chairperson of the Strategy Committee and as a member of the Nomination Committee. Ms. Li Tan, Deputy General Manager, is a member of both the Strategy and Nomination Committees. Mr. Shan Yu, General Manager, and Mr. Zhang Ping also serve as Executive Directors. The company's Independent Non-executive Directors are Mr. Huang Peng, Chairperson of the Audit Committee and member of the Remuneration and Evaluation Committee; Mr. Yi Ming, Chairperson of the Remuneration and Evaluation Committee and member of the Audit and Nomination Committees; and Mr. Pu Hong, Chairperson of the Nomination Committee and member of the Strategy and Audit Committees.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0070":"员工持股","BK0239":"医药制造","002399":"海普瑞","BK0188":"融资融券"},"translate_title":"深圳海普瑞药业向港交所提交董事会名单","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002399":0.9},"content_text":"Shenzhen Hepalink Pharmaceutical Files Board of Directors List to HKEX\n    \n\nShenzhen Hepalink Pharmaceutical Group Co. Ltd. has filed an updated list of directors with the Hong Kong Stock Exchange. The board is led by Executive Director and Chairman Mr. Li Li, who also serves as Chairperson of the Strategy Committee and as a member of the Nomination Committee. Ms. Li Tan, Deputy General Manager, is a member of both the Strategy and Nomination Committees. Mr. Shan Yu, General Manager, and Mr. Zhang Ping also serve as Executive Directors. The company's Independent Non-executive Directors are Mr. Huang Peng, Chairperson of the Audit Committee and member of the Remuneration and Evaluation Committee; Mr. Yi Ming, Chairperson of the Remuneration and Evaluation Committee and member of the Audit and Nomination Committees; and Mr. Pu Hong, Chairperson of the Nomination Committee and member of the Strategy and Audit Committees.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shenzhen Hepalink Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251216-11957365), on December 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591731983","isCrawlerRequest":true}